- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03337334
Effects of High Amplitude and Focused tACS on Entraining Physiological Tremor
November 8, 2017 updated by: Ahmad Khatoun, KU Leuven
Transcranial alternating current stimulation (tACS) is a noninvasive neuromodulation method that works by passing alternating electric current between electrodes where at least one of them is attached to the head.
While tACS applied over the motor cortex at the general applied amplitude (1 mA) and using patch electrodes has been shown to entrain physiological tremor in healthy volunteers, the aim of this study is to test the feasibility of using high-amplitude tACS and to assess the effect of different electrode montages and stimulation sites in entraining physiological tremor.
First, 10 subjects (arm 1) will be stimulated with 2 mA current amplitude applied between saline soaked patch square electrodes and comparison will be done between motor cortex stimulation and peripheral cortex stimulation.
Then, 10 subjects (arm 2) will be stimulated using focused 4x1 montage with gel-filled cup-electrodes and 5 mA amplitude and comparison will be made between motor cortex and occipital cortex stimulation.
Three outcome measurements will be measured during the experiments which are: tremor entrainment, phosphene intensity and phosphene threshold.
Study Overview
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Above 18
- signed informed written consent
Exclusion Criteria:
- Pregnancy
- History of Epilepsy
- Family history of Epilepsy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Non-Focused stimulation
Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 2 mA peak amplitude (reduced if not uncomfortable).
One 5*5 cm2 square patch electrodes are placed over the Motor cortex and the Prefrontal cortex respectively and a common return electrode of 10*10 cm2 over the ankle.
Each subject follows three sessions of 12 min length each.
During each session the tremor is measured while interleaving between Motor cortex stimulation, Prefrontal cortex stimulation and No stimulation.
By the end of each session we get 4 min of Motor Cortex stimulation, 4 min of Prefrontal Cortex stimulation and 4 min of No stimulation.
|
tACS applied between the stimulation electrodes at tremor frequency
|
|
Other: Focused stimulation
Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 5 mA peak amplitude (with the help of local anesthetic cream and amplitude is reduced if not uncomfortable).
A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex and the occipital cortex respectively.
Each subject follows three sessions of 12 min length each.
During each session the tremor is measured while interleaving between Motor cortex stimulation, Occipital cortex stimulation and No stimulation.
By the end of each session we get 3 min of Motor Cortex stimulation, 3 min of occipital Cortex stimulation and 6 min of No stimulation.
|
tACS applied between the stimulation electrodes at tremor frequency
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tremor-stimulation phase entrainment
Time Frame: During the 36 minutes of all sessions (3 sessions each of is 12 minutes)
|
phase locking value was calculated between the tremor signal measured using accelerometer and the stimulation signal
|
During the 36 minutes of all sessions (3 sessions each of is 12 minutes)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Phosphene rating
Time Frame: Measured up to 5 minutes before the start of the stimulation sessions and lasts for 10 seconds of stimulation after which the subject gives the rating
|
The subject is asked to rate the phosphene intensity during the stimulation using a visual analog scale from 0 to 10. Zero means no phosphene is perceived and the number starts to increase as the phosphene perception intensity increases to reach 10 if the subject observe only a white view
|
Measured up to 5 minutes before the start of the stimulation sessions and lasts for 10 seconds of stimulation after which the subject gives the rating
|
|
Phosphene threshold
Time Frame: Measured 3 minutes before the start of the stimulation sessions and lasts up to 2 minutes. Stimulation at each amplitude lasts for 10 sec.
|
Stimulation amplitude at which the subject starts to perceive phosphene.
Stimulation starts with 0 mA amplitude and then increased gradually until phosphene is perceived (or reaching maximum amplitude).
|
Measured 3 minutes before the start of the stimulation sessions and lasts up to 2 minutes. Stimulation at each amplitude lasts for 10 sec.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2016
Primary Completion (Actual)
April 1, 2017
Study Completion (Actual)
April 1, 2017
Study Registration Dates
First Submitted
November 1, 2017
First Submitted That Met QC Criteria
November 8, 2017
First Posted (Actual)
November 9, 2017
Study Record Updates
Last Update Posted (Actual)
November 9, 2017
Last Update Submitted That Met QC Criteria
November 8, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S57869
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tremor, Limb
-
University Hospital, MontpellierCompletedUpper Limb Tremor InvalidatingFrance
-
KU LeuvenCompleted
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Completed
-
Abbott Medical DevicesCompletedEssential Tremor | Tremor | Action Tremor | Tremor, LimbUnited States
-
David M. SimpsonIpsenUnknown
-
Merz Pharmaceuticals GmbHCompletedEssential Tremor of the Upper LimbUnited States, Canada, Poland
-
AbbVieCompletedUpper Limb Essential Tremor (UL ET)United States, Canada
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedSevere Upper Limb Tremor Refractory to Medical TherapyItaly
-
Icahn School of Medicine at Mount SinaiAllerganCompletedFocal Dystonia | Spasticity | Tremor, LimbUnited States
-
Emory UniversityCompletedEssential Tremor | Essential Vocal Tremor | Essential Voice Tremor | Voice Tremor | Vocal TremorUnited States
Clinical Trials on tACS at tremor frequency
-
KU LeuvenCompleted
-
Donders Centre for Cognitive NeuroimagingParkinson's FoundationCompleted
-
Hôpital le VinatierRecruiting
-
Università Vita-Salute San RaffaeleAlessia Santoni; Sara Stottmeier; Klara Hemmerich; Giuseppe Di Dona; Luigi Ferini-StrambiRecruitingHuman Brain and CognitionItaly
-
Amsterdam UMC, location VUmcRecruitingAlzheimer Disease | Mild Cognitive ImpairmentNetherlands
-
Ecole Polytechnique Fédérale de LausanneActive, not recruitingStroke | Parkinson Disease | Visual ImpairmentSwitzerland
-
University of North Carolina, Chapel HillCompleted
-
Stephan EliezRecruitingtACS | 22Q11 Deletion SyndromeSwitzerland
-
University of ChicagoMichael J. Fox Foundation for Parkinson's ResearchCompletedParkinson's DiseaseUnited States
-
National Institute of Neurological Disorders and...CompletedRepetitive TMS (rTMS) | Sham rTMS | Bilateral rTMS | Unilateral rTMSUnited States